Herpes Zoster News and Research

RSS

Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.

The association between viral infections and glioma risk

The causal relationship between viral infection and glioma.

7 Dec 2023

Herpes zoster vaccination and healthy aging: Study connect the dots

Vaccination with recombinant zoster vaccine (RZV) prevents Herpes Zoster (HZ) infection.

30 Nov 2023

Live shingles vaccine highly effective in the first year after vaccination and then wanes substantially

The effectiveness of live zoster (shingles) vaccine is highest in the first year after vaccination and then wanes substantially.

8 Nov 2023

Pharmacists can play key role in boosting HPV vaccination rates

HPV, or human papillomavirus, is the most common sexually transmitted infection. It is also the leading cause of cervical cancer.

3 Oct 2023

Stem cell transplant offers hope for patients with multiple sclerosis

Stem cells harvested from a person's own bone marrow or blood, can safely slow progression of the most common form of the autoimmune disease, multiple sclerosis, or MS as it's usually known, finds research published online in the Journal of Neurology Neurosurgery & Psychiatry.

26 Sep 2023

Stem cell transplant offers hope for MS patients, study finds

Autologous hematopoietic stem cell transplantation, or aHSCT for short, is usually used to treat blood cancers, and involves harvesting stem cells from the person's own bone marrow or blood followed by chemotherapy and antibody treatment.

25 Sep 2023

Prior vaccinations may help protect against Alzheimer's disease

Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer's disease, according to new research from UTHealth Houston.

16 Aug 2023

HIV diagnoses increases more than three-fold after implementing targeted testing in EDs

Targeted testing for HIV in emergency departments has great potential for increasing diagnoses, this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark, (15-18 April), will hear.

10 Apr 2023

Study finds recent shingles infection increases the risk of myocardial infarction

Researchers assessed myocardial infarction (MI) risk after zoster infection.

30 Mar 2023

Cellular and humoral responses and the safety of recombinant and inactivated SARS-CoV-2 vaccines in chronic kidney disease patients

Researchers investigated the B cell and humoral immune responses elicited against inactivated and recombinant SARS-CoV-2 vaccines and their safety profiles in patients with CKD.

8 Feb 2023

Study on bacterial infection in older individuals

The older population is prone to microbial infections, which can lead to death. Hence, it is important to understand why this group is vulnerable to microbial infection, especially bacterial infection. A recent Scientific Reports study linked data from two sources to understand the determining factors for microbial infection in the older population in the UK.

11 Jan 2023

Shingles linked with higher long-term risk of major cardiovascular event

A new study by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, demonstrated that shingles, also known as herpes zoster, is associated with an almost 30% higher long-term risk of a major cardiovascular event such a stroke or heart attack.

22 Nov 2022

New EULAR recommendations for screening and treating infections in AIIRD patients

It is already known that people who are immunocompromised are more prone to infections. Chronic and opportunistic infections are often found in people with an AIIRD, and may be linked to some of the immunosuppressive and immunomodulatory treatments used to treat these rheumatic diseases.

22 Nov 2022

CU Anschutz study details the mechanisms behind the link between shingles and strokes

Scientists investigating why people who have had shingles are at a higher risk of stroke, now believe the answer lies within lipid vesicles called exosomes that shuttle proteins and genetic information between cells, according to new research from the University of Colorado Anschutz Medical Campus.

28 Oct 2022

25 years on, varicella vaccination reports impressive success in the USA

New research suggests that 25 years on, varicella vaccination continues to report impressive success in the USA.

26 Oct 2022

IRIS Registry presents latest eye research at AAO 2022

The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022 Gather, the 126th annual meeting of the American Academy of Ophthalmology.

30 Sep 2022

COVID-19 booster shots essential for maintaining long-term immunity against infection in older adults

In a study of more than 80 men and women from Baltimore, Maryland, Johns Hopkins researchers have added to evidence that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults.

29 Sep 2022

How effective are live-attenuated SARS-CoV-2 vaccines?

Researchers opined on the use of live-attenuated whole virus vaccines as COVID-19 vaccines.

26 Sep 2022

ViruStop, ACROBiosystems’s new brand accelerating the process of vaccine development and approval

"Welcome to ViruStop!" Recently, ACROBiosystems officially announced the launch of a new brand, ViruStop. ViruStop is specifically designed for virus research and development, committing to accelerating the process of infectious diseases vaccine research, development and approval.

From ACROBiosystems 1 Aug 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022